



SciGen Announces Marketing Alliance with Abbott Laboratories in the Philippines for its recombinant human Insulin SciLin™.

8th December 2006: SciGen Limited (ASX: SIE) announces a new partnership between Abbott Laboratories and SciGen Limited whereby Abbott will be co-promoting SciGen's SciLin™ (recombinant human insulin) throughout the Philippines. This will enable SciGen to increase its sales coverage throughout the country.

The Abbott/SciGen alliance will increase the reach and awareness of a safe, efficacious and affordable insulin. This beneficial alliance will also focus on augmenting diabetes education for patients on the early use of insulin in controlling the disease. This also gives Abbott a companion product that will enhance their existing diabetes product line, Cardio-Metabolic lines, Anti-hypertensive, and Glucose Meters. This is the start of a relationship that could potentially cover other countries in the Asia Pacific region.

About SciLin™:

SciLin™ is a second-generation recombinant human insulin expressed in *E. coli*. SciLin™ contains insulin produced by recombinant DNA technology using a special non-disease producing strain of *E. coli* cell bacteria. The insulin molecule in SciLin™ is identical to natural human insulin in composition and in three-dimensional conformation. SciLin™ is used for type I and type II diabetes.

The need for Generic Insulin continues to grow. Currently, the total world market for insulin is estimated to be US\$3.6 billion per annum and that for all diabetes therapeutics is forecast to grow by 20% per annum over the medium term. SciGen's target regions include India, China and Pakistan, which rank among the five largest populations of diabetes in the world.

About Abbot Laboratories:

Abbott is a global health care company with an extensive portfolio, which includes nutritional products, laboratory diagnostics, medical devices, Intravenous solutions, pharmaceutical, and Biopharmaceuticals and veterinary medicine. For over 100 years, Abbott has continued to strive to advance medical science to help people improve their lives through better health. Abbott markets its products in more than 130 countries worldwide.

About SciGen:

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.



SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherlands

Further information:

Company – Investor Relations	Company
Ms. Maria Arroyan SciGen Australia +61 2 9234 1700 email: mariaaroyan@scigen.com.au	Saul Mashaal Chairman, Founder & CEO SciGen Ltd. + 61 2 9234 1700 +65 9630 5691 (Mobile)